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Neonatal lupus erythematosus is an uncommon disease
associated with maternal autoantibodies to proteins
of the Ro/La (SSA/SSB) family. The clinical ¢ndings
most often reported are third- degree heart block and
cutaneous lupus lesions, but a signi¢cant number of
children have cardiomyopathy, hepatobiliary disease,
or hematologic cytopenias. The consistent presence of
maternal autoantibodies and the transient nature of the
disease implicate maternal autoantibodies as the cause
of the disease, and developing animal models support
the concept that the autoantibodies are pathogenic.
Only a minority of babies exposed to the autoantibodies
develop disease, however, and mothers and their babies
have di¡erent disease manifestations. Thus, additional
factors are likely to be important in determining disease
expression. Key words: autoantibody/heart block/Ro/La.
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H
alf a century ago, McCuistion and Schoch de-
scribed a case of transient lupus skin lesions occur-
ring in a baby whose mother was ANA positive
(McCuistion and Schoch, 1954). Theirs was the ¢rst
report of neonatal lupus (NLE). Although NLE is
an uncommon disease, several hundred cases have been reported.
It is now known that NLE occurs in the o¡spring of mothers
who have anti-Ro (SSA) autoantibodies and that it may manifest
as skin, cardiac, hepatobiliary, or hematologic disease.This review
will focus on recent advances in the understanding of the clinical
features of NLE and its pathogenesis.
CLINICAL FINDINGS
Cutaneous NLE Cutaneous NLE lesions typically appear at a
few days to weeks after birth, but they have been noted at birth
in some cases (Lee, 1999). Lesions are most likely to occur on the
face and scalp, but may also occur on the extremities and trunk,
including the diaper area. The morphology is characteristically
that of an annular erythema with central clearing and raised red
borders (Fig 1), but lesions may sometimes have ¢ne scale or
crusting. Histology of the lesions is identical to that of subacute
cutaneous lupus of adults, with keratinocyte damage and a
super¢cial mononuclear cell in¢ltrate, but little or no follicular
plugging or scarring. Resolution of active disease takes place
within weeks or months, although dyspigmentation may persist for
many months or years and permanent telangiectasia may occur.
A review of 18 cases of NLE evaluated at the University of
Colorado noted a predominance of females (14 females, 4 males)
and a frequent occurrence of periorbital lesions that impart an
‘‘owl eye’’ or ‘‘eye mask’’ appearance (Weston et al, 1999).
Photosensitivity was observed in 12 cases, and features of cutis
marmorata telangiectasia congenita were observed in 4. Residual
telangiectasias were present in 4 children. Remarkably, in 17 of 18
cases the diagnosis of NLE was not suspected until the
dermatology consultation.
It is common in NLE for there to be only one organ noted to
be a¡ected, and indeed the skin was apparently the only organ
a¡ected in 12 of 18 cases. In 2 cases, there was skin disease and
heart block; in 3 cases, skin lesions, hepatobiliary disease, and
thrombocytopenia; and in 1 case, skin disease, heart block, and
thrombocytopenia. Although heart block is the ¢nding of NLE
most emphasized, it appears that children who have NLE skin
lesions may be as likely to have hepatobiliary or hematologic
disease as heart disease.
The Research Registry for Neonatal Lupus, established in
1994, is a repository of cases from the United States and is likely
the largest collection of cases in the world. The clinical
characteristics of 57 cases of cutaneous NLE in the absence of
heart block were reported from the registry database. These
¢ndings con¢rm female predominance (37 females, 20 males),
frequent involvement of the skin of the face and scalp
(especially the periocular skin), frequent photosensitivity, and
occasional residual telangiectasia or dyspigmentation (Neiman
et al, 2000).
Cardiac NLE The cardiac disease of NLE is characteristically
congenital complete (third-degree) heart block (CHB) (Lee,
1999). CHB almost always begins in utero during the second or
third trimester. Occasionally, a lesser degree of block that may
progress to third degree is initially noted. Autopsy studies have
shown a replacement of the atrioventricular nodal area by
¢brosis and calci¢cation. If this ¢nding is also representative of
the cardiac pathology in children who survive, replacement of
nodal tissue by ¢brosis explains why CHB is almost always
permanent.
Perhaps surprisingly, some children with CHB are able to
compensate for the slow heart rate and do not require therapy.
Many require pacemaker implantation, however. In some cases,
cardiomyopathy occurs in addition to the conduction system
abnormality. In children with signi¢cant cardiac muscle involve-
ment, correction of the heart rate with a pacemaker may not
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su⁄ce to correct heart failure and the outcome is often fatal.
Most cases of signi¢cant cardiac muscle involvement are evident
at birth or shortly thereafter, but cases of cardiomyopathy have
developed a few months after birth, indicating the need for
continued close monitoring of children who have cardiac NLE
(Taylor-Albert et al, 1997).
The registry reported information from 113 cases of cardiac
NLE (Buyon et al, 1998). There were approximately equal
numbers of males and females. Heart block was usually detected
in the second or early third trimester, with a median gestational
age at detection of 23 weeks. In this database, 63% of children
required pacemakers and about 20% died as a result of cardiac
failure.
Hepatobiliary disease Almost all cases of hepatobiliary disease
associated with NLE have been in children who had cardiac
or cutaneous lesions, although there have been case reports
of hepatobiliary disease occurring as an isolated ¢nding
(Schoenlebe et al, 1993; Selander et al, 1998). In a review of data
from the registry, the following types of hepatobiliary
involvement were found: (1) liver failure occurring in utero or
shortly after birth and often having the clinical phenotype of
neonatal iron storage disease or neonatal ‘‘hemochromatosis’’;
(2) transient conjugated hyperbilirubinemia occurring in the
¢rst few weeks of life; and (3) transient elevations of amino-
transferases occurring at about two or three months of age (Lee
et al, 2002). Evidence of hepatobiliary involvement was present in
about 10% of cases in the registry. It is quite possible that the
percentage of cases a¡ected is actually higher, as most cases had
no documentation of liver enzymes having been checked.
Hematologic disease Thrombocytopenia has been noted in
several cases of NLE (Watson et al, 1988) and may occur in as
many as 10% of cases of cardiac or cutaneous NLE. It is
transient and often clinically benign, but there has been at least
one case of gastrointestinal bleeding attributed to it (Lee, 1999).
Neutropenia has been reported in NLE only infrequently, but,
it occurred in 5 of the 57 children with cutaneous NLE entered in
the registry (Neiman et al, 2000; Kanagasegar et al, 2002).
Lymphopenia, which has been reported to have some correla-
tion with anti-Ro autoantibodies in adults, has not been a
feature of NLE. Anemia, which has in some cases been char-
acterized as hemolytic anemia, has been reported occasionally.
THERAPY
The management of cutaneous NLE is straightforward. Sun pro-
tection is advisable, and low-potency topical steroids may help
decrease the erythema. Because the cutaneous lesions apparently
produce no discomfort in the baby and spontaneously resolve,
there is little justi¢cation for administering systemic therapies
such as corticosteroids or antimalarials. Residual telangiectasia
may be treated by a vascular laser.
For cardiac disease, pacemaker implantation and medical man-
agement of heart failure is required in many cases. Systemic ster-
oids may be administered to fetuses or babies with heart disease,
but their e⁄cacy has not been clearly established by prospective
controlled studies (Saleeb et al, 1999). In one case of a child with
heart failure and progressive cardiomyopathy, despite pacemaker
implantation, digoxin, captopril, systemic steroids, and IVIg,
plasma exchange were administered (Taylor-Albert et al, 1997).
The plasma exchange was performed based on the hypothesis that
maternal autoantibodies contribute to the disease.The child’s con-
dition stabilized, but it is not possible to conclude whether the
disease course was a¡ected by the treatments given.
Some investigators have touted the use of systemic steroids as
a prophylactic measure administered to the mother during
pregnancy (Shinohara et al, 1999). In my opinion, however,
further data are needed before this approach can be generally
recommended. Systemic steroids are not entirely benign, and
pregnancy outcomes, discussed below, are usually favorable in
any case.
OUTCOMES
Pregnancy NLE is not a common disease, occurring in
perhaps 1 of 20,000 live births (Lee and Weston, 1996). Anti-Ro
autoantibodies, the antibodies most strongly associated with
NLE, are present in about 1 of 200 persons. Thus, even though
virtually all women who have a baby with NLE have anti-Ro
autoantibodies, very few women who have anti-Ro will have a
baby with NLE.
It appears that there are anti-Ro^positive women who have
a higher risk of having a baby with NLE. Studies from
rheumatology clinics indicate that the risk for anti-Ro^positive
women with SLE and related diseases may be in the 5%^15%
range (Ramsey-Goldman et al, 1986; Lockshin et al, 1988).
Reports of the risk for women, symptomatic or not, who have
already had one baby with NLE having an a¡ected baby in a
subsequent pregnancy are 8%^65%, with an overall risk of 25%
if data from the ¢ve studies cited here are combined (McCune
et al, 1987; Julkunen et al, 1993a;Waltuck and Buyon, 1994; Buyon
et al, 1998; Neiman et al, 2000).
Children The short-term outcomes for children were discussed
above. Except for the few cases of children with liver failure, the
children who do not have cardiac disease have rather prompt
resolution of disease activity and a good short-term outcome.
For children with cardiac disease, there is signi¢cant mortality
and morbidity.
It may be expected that in the long run some children who
have NLE will later develop autoimmune disease, based on the
fact that there is a family history of autoimmunity (i.e., a mother
who has autoantibodies). The question is whether the risk for
autoimmune disease is slightly or substantially higher than that
of the general population. At this time, there is not enough
information to draw a conclusion. It is noteworthy, however,
that in a long-term registry follow-up of 49 NLE children and
their 45 una¡ected siblings, 6 children who had NLE later
developed autoimmune diseases or diseases thought possibly to
be autoimmune, whereas none of the una¡ected siblings
developed disease (Martin et al, 2002 ). Speci¢cally, of the 49
children who had NLE, there were 2 with juvenile rheumatoid
arthritis, 1 with Hashimoto’s thyroiditis, 1 with psoriasis and
iritis, 1 with diabetes mellitus and psoriasis, and 1 with
congenital hypothyroidism and nephrotic syndrome. In the
group of 45 una¡ected siblings, there were 2 children with
Figure1. Characteristic annular erythematous lesions on the face of a
child with cutaneous neonatal lupus.
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positive ANA but none with symptoms suggestive of
autoimmune disease.
Maternal symptoms Perhaps half of women who have a child
with NLE are asymptomatic at the time of presentation of the
child.With time, most develop symptoms, which are rarely the
same as those of their children. Heart block has not been
reported in mothers of babies with NLE, and cutaneous lupus
lesions are unusual. In two studies, maternal symptoms were
most consistent with Sj˛gren’s syndrome (McCune et al, 1987;
Julkunen et al, 1993b), whereas in other studies diagnoses of
systemic lupus erythematosus or undi¡erentiated connective
tissue disease were more frequently seen (Waltuck and Buyon,
1994; Press et al, 1996).
AUTOANTIBODIES AND NLE PATHOGENESIS
The autoantibodies originally associated with NLE are anti-Ro,
also called anti-SSA (Franco et al, 1981). In sera containing anti-
Ro, several autoantibody speci¢cities may be present concur-
rently. These include antibodies to the originally described Ro
protein of 60 kDa, antibodies to a nonhomologous protein called
52-kDa Ro, and antibodies to the La (SSB) protein. A compre-
hensive study examining anti-Ro^related autoantibody speci¢ci-
ties in 20 NLE maternal sera using Ouchterlony assays, western
blotting, and ELISA found antibodies to 60-kDa Ro in all 20,
antibodies to 52-kDa Ro in 18, and antibodies to La in 9 (Lee
et al, 1994).
Other autoantibody speci¢cities associated with NLE include
antibodies to calreticulin (Lieu et al, 1989), a 57-kDa protein
(Maddison et al, 1995), a 75-kDa phosphoprotein (Wang et al,
1999), alpha-fodrin (Miyagawa et al, 1998), the neonatal heart M1
muscarinic acetylcholine receptor (Borda and Sterin-Borda,
2001), and, in a few cases of cutaneous NLE, U1RNP (Provost
et al, 1987).
From a diagnostic standpoint, Ouchterlony (immunodi¡u-
sion) assays for antibodies to Ro and La remain the most valuable,
clinically relevant serologic test.
Autoantibodies and disease It is reasonable to hypothesize
that autoantibodies cause NLE. They are invariably present in
NLE sera, and they are not random but rather are of a particular
set of speci¢cities associated with the Ro family. Disease activity
in NLE occurs while maternal autoantibodies are present in the
child’s circulation and resolves at or before the time that maternal
autoantibodies are fully metabolized by the child.
Examination of antibody deposits in human tissue have shown
that anti-Ro antibodies are found in both a¡ected and una¡ected
organs (Lee et al, 1987; Lee et al, 1989; Reichlin et al, 1994). This is
perhaps not surprising, given that the Ro and La proteins are
normally found in all organs. It does not, however, provide an
explanation for why NLE involves heart, skin, and a few other
sites but fails to involve many other organs.
In my lab, maternal sera from cutaneous NLE and cardiac
NLE cases have been compared in several assays in order to
determine whether there are di¡erences in the maternal
autoantibodies that correlate with di¡erences in the expression
of disease. These studies have been largely negative. Cutaneous
NLE and cardiac NLE autoantibodies were not detectably
di¡erent with regard to IgG antibody subclass (Bennion et al,
1990); western blotting patterns using skin extract, heart extract,
and extract from other organs; or precipitation of hY RNA
associated with 60-kDa Ro (Lee et al, 1996). One di¡erence
detected was an appreciably higher titer of antibodies to 60-kDa
Ro in cardiac NLE sera compared with cutaneous NLE sera,
po 0.02 (Lee et al, 1994).
In addition to the question of organ speci¢city in NLE, there
is the question of why fetuses or newborns develop disease while
their mothers exposed to the same autoantibodies are una¡ected
or a¡ected in a di¡erent way. It has been reported that there are
isoforms of 52-kDa Ro that are expressed di¡erently during
di¡erent stages of gestation (Buyon et al, 1997). Also, RNA
associated with 60 kDa Ro are expressed di¡erently at di¡erent
stages of gestation (Fraire-Velazquez et al, 1999). Whether the
di¡erential expression leads to disease susceptibility has yet to be
determined.
ANIMAL MODELS OF NLE
Reproduction of NLE in an animal model has been attempted
by many investigators. Several years ago, my lab injected preg-
nant guinea pigs with anti-Ro/La^containing human maternal
NLE serum (Lee and Coulter, unpublished data 1986). The pups
were examined for antibody deposits and development of disease.
Human IgG deposits were found in all pups and presented uni-
formly in all organs (Fig 2). These ¢ndings are similar to those in
human tissues examined. None of the pups developed disease,
although the number of animals tested was rather small by com-
parison to that in later studies using mice.
In 1992, Alexander and coworkers demonstrated abnormalities
of repolarization in isolated rabbit cardiac muscle perfused with
anti-Ro^positive serum (Alexander et al, 1992). Garcia and collea-
gues reported heart block in isolated rabbit hearts perfused with
anti-Ro^positive serum or with puri¢ed anti-52-kDa Ro (Garcia
et al, 1994; Viana et al, 1998). Boutjdir and coworkers reported the
reproduction of heart block in isolated rat hearts and also the in-
duction of bradycardia and prolonged PR interval (but not com-
plete heart block) in newborn mice whose mothers received
human anti-Ro/La^containing IgG during pregnancy (Boutjdir
et al, 1998; Mazel et al, 1999). Miranda-Carus observed conduction
abnormalities in about 10% of mouse pups born to mothers im-
munized to 60-kDa Ro, 52-kDa Ro, or La (Miranda-Carus et al,
1998). In pups whose mothers were immunized to 52-kDa Ro,
the conduction abnormality was third-degree block in some
cases. Histologic ¢ndings in the a¡ected hearts were not reported.
Overall, these studies, subject to some limitations, provide strong
support for the hypothesis that anti-Ro/La autoantibodies are
pathogenic.
A mechanistic link between anti-52-kDa Ro and cardiac dis-
ease has been proposed by Eftekhari and colleagues, who identi-
¢ed a cross-reactivity between 52-kDa Ro and the serotoninergic
5-HT4 receptor (Eftekhari and Salle 2000; Eftekhari and Roegel
2001). Puri¢ed anti-5-kDa Ro/anti-5-HT4-receptor antibodies
antagonized the serotonin-induced L-type calcium channel
Figure 2. Human IgG deposits detected by direct immuno£uores-
cence in cardiac muscle of a guinea pig pup whose mother was in-
jected during pregnancy with human maternal neonatal lupus serum.
Antibody deposits were observed in all organs tested, including organs
not known to be a¡ected in neonatal lupus.
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activation on human atrial cells. Female mice immunized to pro-
duce antibodies to 52-kDa Ro and 5-HT4-receptor peptides gave
birth to pups who had bradycardia, type I or II atrioventricular
block, skin rashes, or neuromotor problems. The rashes were not
characterized histologically. Inspection of the hearts revealed an
abnormally small size, with underdevelopment of the ventricles.
The histology of the atrioventricular region was not reported. As
in the human disease and the mouse model of Miranda-Carus,
only a minority of pups developed heart block. This model pro-
vides supporting evidence that NLE autoantibodies cause disease,
and it raises the possibility that disease is induced as a result of
antibody cross-reactivities. The degree to which this model reca-
pitulates or may be re¢ned to recapitulate human NLE remains
to be elucidated.
Tran and coworkers injected pregnant mice with human anti-
Ro/La^containing sera (Tran et al, 2002). The pups were noted to
have human IgG binding to apoptotic cells in the heart, skin,
liver, and bone, but not in the thymus, lung, brain, or gut. In
studies of cultured human cells, it had been reported that
anti-Ro/La-antibody binding to apoptotic cardiac cells increases
secretion of TNF-a from cultured macrophages (Miranda-Carus
et al, 2000) and results in di¡erentiation of cardiac ¢broblasts to a
scarring phenotype (Clancy et al, 2002). In this animal model,
however, the apoptotic complexes were not associated with an
in£ammatory reaction and gross ¢ndings of NLE were not
observed.
SUMMARY
NLE is a disease strongly associated with maternal autoantibodies
to Ro and La. These autoantibodies cross the placenta and are
found in the child’s circulation. Disease activity resolves by the
time the maternal autoantibodies are metabolized. Much circum-
stantial and experimental evidence implicates autoantibodies in
the pathogenesis of NLE, but the full explication of disease
pathogenesis has yet to be accomplished.
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